[go: up one dir, main page]

CL2008003035A1 - Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bcl-2, permite tratar un cancer que exprese el cd 20. - Google Patents

Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bcl-2, permite tratar un cancer que exprese el cd 20.

Info

Publication number
CL2008003035A1
CL2008003035A1 CL2008003035A CL2008003035A CL2008003035A1 CL 2008003035 A1 CL2008003035 A1 CL 2008003035A1 CL 2008003035 A CL2008003035 A CL 2008003035A CL 2008003035 A CL2008003035 A CL 2008003035A CL 2008003035 A1 CL2008003035 A1 CL 2008003035A1
Authority
CL
Chile
Prior art keywords
expresses
cancer
drug
prepare
active agent
Prior art date
Application number
CL2008003035A
Other languages
English (en)
Inventor
Thomas Friess
Christian Klein
Pamela Strein
Pablo Umana
Original Assignee
Hoffmann La Roche
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38904707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Glycart Biotechnology Ag filed Critical Hoffmann La Roche
Publication of CL2008003035A1 publication Critical patent/CL2008003035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bel-2, permite tratar un cáncer que exprese el cd 20.
CL2008003035A 2007-10-15 2008-10-14 Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bcl-2, permite tratar un cancer que exprese el cd 20. CL2008003035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07020120 2007-10-15

Publications (1)

Publication Number Publication Date
CL2008003035A1 true CL2008003035A1 (es) 2010-01-11

Family

ID=38904707

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003035A CL2008003035A1 (es) 2007-10-15 2008-10-14 Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bcl-2, permite tratar un cancer que exprese el cd 20.

Country Status (16)

Country Link
US (6) US20090098118A1 (es)
EP (2) EP2203185A1 (es)
JP (1) JP5416124B2 (es)
KR (1) KR101278395B1 (es)
CN (1) CN101827611B (es)
AR (1) AR068862A1 (es)
AU (1) AU2008314068B2 (es)
BR (1) BRPI0818673A2 (es)
CA (1) CA2702300A1 (es)
CL (1) CL2008003035A1 (es)
IL (1) IL204744A0 (es)
MX (1) MX2010003815A (es)
PE (1) PE20090966A1 (es)
RU (1) RU2541805C2 (es)
TW (1) TWI430809B (es)
WO (1) WO2009049841A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO2008144506A1 (en) * 2007-05-16 2008-11-27 University Of Maryland, Baltimore Apoptotic pathway targeting for the diagnosis and treatment of cancer
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PT2435432E (pt) * 2009-05-26 2015-10-13 Abbvie Bahamas Ltd Agentes indutores de apoptose para o tratamento de cancro e doenças imunes e autoimunes
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
SG181916A1 (en) * 2009-12-22 2012-08-30 Abbott Lab Abt-263 capsule
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2848342A1 (en) * 2010-08-09 2012-02-16 University Of South Florida Acylsulfonamides and processes for producing the same
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
EP2651976A1 (en) * 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
KR101274731B1 (ko) * 2011-01-18 2013-06-18 동아대학교 산학협력단 레스베라트롤의 유사체인 ｈｓ－１７９３ 또는 이의 약학적으로 허용가능한 염을 유효성분으로 하는 전립선 암 치료용 약학적 조성물
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN102222176A (zh) * 2011-06-01 2011-10-19 山东大学 一种快速发现以Bcl-2蛋白为靶点的先导化合物的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2892557A1 (en) * 2012-09-07 2015-07-15 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
HRP20191585T1 (hr) * 2015-05-26 2019-11-29 Hoffmann La Roche Kombinirana terapija protutijela anti cd20 s inhibitorima bcl-2 i mdm2
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
MX2020009759A (es) * 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN115996760A (zh) * 2020-04-27 2023-04-21 阿鲁纳生物股份公司 用于中枢神经系统递送的结合剂及其用途
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US371191A (en) 1887-10-11 Cloth-sponging machine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2172153C (en) 1993-09-20 2010-03-09 John C. Reed Regulation of bcl-2 gene expression
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
MXPA00011248A (es) 1998-05-15 2004-09-06 Imclone Systems Inc Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004056971A2 (en) 2002-12-19 2004-07-08 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PL224787B1 (pl) 2003-01-22 2017-01-31 Roche Glycart Ag Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
RU2360913C2 (ru) 2003-05-30 2009-07-10 Жемэн Икс Фармасьютикалз Канада Инк. Тригетероциклические соединения, фармацевтические композиции на их основе и способы лечения рака
EP2236172A1 (en) * 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
EA025962B1 (ru) * 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JP2007530568A (ja) * 2004-03-25 2007-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ゴシポール共結晶およびその使用
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
WO2006089397A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
DK1888550T3 (da) * 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
ZA200710496B (en) * 2005-06-02 2009-04-29 Astrazeneca Ab Antibodies directed to CD20 and used thereof
WO2007031875A2 (en) 2005-08-26 2007-03-22 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity

Also Published As

Publication number Publication date
PE20090966A1 (es) 2009-07-13
MX2010003815A (es) 2010-08-04
KR101278395B1 (ko) 2013-06-24
AU2008314068A1 (en) 2009-04-23
EP2203185A1 (en) 2010-07-07
CN101827611B (zh) 2014-01-15
EP2604277A1 (en) 2013-06-19
US20110287006A1 (en) 2011-11-24
WO2009049841A1 (en) 2009-04-23
JP5416124B2 (ja) 2014-02-12
TW200920401A (en) 2009-05-16
RU2541805C2 (ru) 2015-02-20
AU2008314068B2 (en) 2014-01-16
IL204744A0 (en) 2010-11-30
CA2702300A1 (en) 2009-04-23
US20120276085A1 (en) 2012-11-01
RU2010118448A (ru) 2012-05-20
US20150056186A1 (en) 2015-02-26
JP2011500521A (ja) 2011-01-06
US20140004104A1 (en) 2014-01-02
KR20100056559A (ko) 2010-05-27
BRPI0818673A2 (pt) 2015-09-08
CN101827611A (zh) 2010-09-08
US20090098118A1 (en) 2009-04-16
TWI430809B (zh) 2014-03-21
AR068862A1 (es) 2009-12-09
US20110086025A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
CL2008003035A1 (es) Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bcl-2, permite tratar un cancer que exprese el cd 20.
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
MX395149B (es) Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
UY37494A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2008002613A1 (es) Uso de una combinacion de un anticuerpo anti-cd20 de tipo i con un anticuerpo anti-cd20 de tipo ii para tratar cancer que expresa cd20.
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
AR077629A1 (es) Mimetico de smac